Importantly, antibodies targeting HER-3 such as MM-121 (ClinicalTrials.gov: NCT01451632), RG7116 (ClinicalTrials.gov: NCT01482377) and U3–1287 are currently being tested in several clinical trials across various patient populations, including CRC patients. The gene discussed is ERBB3; the disease is colorectal carcinoma.